{"id":"lactobacillus-casei","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance (bloating, gas)"},{"rate":null,"effect":"Mild abdominal discomfort"}]},"_chembl":{"chemblId":"CHEMBL2109070","moleculeType":"Unknown"},"_dailymed":{"setId":"216b32ae-335d-406e-a243-88aa6697a398","title":"FUSION (VITAMIN C, FERROUS FUMARATE, POLYSACCHARIDE IRON COMPLEX, LACTOBACILLUS CASEI (KE-99)) CAPSULE [U.S. PHARMACEUTICAL CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L. casei produces lactic acid and bacteriocins that inhibit pathogenic bacteria, strengthens the intestinal barrier function, and stimulates both innate and adaptive immune responses through interaction with gut-associated lymphoid tissue. This leads to improved digestive health, enhanced immune tolerance, and potential reduction of gastrointestinal and systemic infections.","oneSentence":"Lactobacillus casei is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system to promote gastrointestinal and systemic health.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:23.299Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastrointestinal health maintenance"},{"name":"Antibiotic-associated diarrhea prevention"},{"name":"Immune system support"}]},"trialDetails":[{"nctId":"NCT06810141","phase":"","title":"ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer","status":"AVAILABLE","sponsor":"ImmunityBio, Inc.","startDate":"","conditions":"NMIBC","enrollment":""},{"nctId":"NCT05568498","phase":"PHASE2","title":"Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-01-20","conditions":"Parkinson Disease, Depression, PARKINSON DISEASE (Disorder)","enrollment":60},{"nctId":"NCT06833073","phase":"PHASE2","title":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-11","conditions":"Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ","enrollment":308},{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000},{"nctId":"NCT02138734","phase":"PHASE1, PHASE2","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2014-07-21","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":596},{"nctId":"NCT05037279","phase":"PHASE3","title":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","status":"RECRUITING","sponsor":"Verity Pharmaceuticals Inc.","startDate":"2024-04-24","conditions":"Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence","enrollment":540},{"nctId":"NCT05714202","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-23","conditions":"Bladder Cancer","enrollment":1135},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":"Urinary Bladder Neoplasms","enrollment":15},{"nctId":"NCT07475299","phase":"NA","title":"Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2026-04","conditions":"Irritable Bowel Syndrome (IBS)","enrollment":8},{"nctId":"NCT04452591","phase":"PHASE3","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","status":"ACTIVE_NOT_RECRUITING","sponsor":"CG Oncology, Inc.","startDate":"2020-10-27","conditions":"Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer","enrollment":190},{"nctId":"NCT07474519","phase":"PHASE4","title":"Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-02-26","conditions":"Non-Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT05316155","phase":"PHASE1, PHASE2","title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-04-11","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":235},{"nctId":"NCT04640623","phase":"PHASE2","title":"A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-18","conditions":"Urinary Bladder Neoplasms","enrollment":220},{"nctId":"NCT07468851","phase":"PHASE1, PHASE2","title":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2026-06-10","conditions":"High-risk Non-muscle-invasive Bladder Cancer","enrollment":180},{"nctId":"NCT06919965","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-10","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":220},{"nctId":"NCT07465497","phase":"NA","title":"Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Instituto Jalisciense de Cancerologia","startDate":"2026-02-27","conditions":"Chemobrain, Breast Cancer, Inflammatory Disease","enrollment":80},{"nctId":"NCT05943106","phase":"PHASE3","title":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-11","conditions":"Non-Muscle- Invasive Bladder Cancer","enrollment":100},{"nctId":"NCT06443944","phase":"","title":"An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG","status":"AVAILABLE","sponsor":"CG Oncology, Inc.","startDate":"","conditions":"Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer","enrollment":""},{"nctId":"NCT07000084","phase":"PHASE3","title":"Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-07-17","conditions":"Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":330},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT04701151","phase":"PHASE4","title":"NORTH-REG Dwell-Time Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2021-02-03","conditions":"Side Effect of Drug","enrollment":314},{"nctId":"NCT05538663","phase":"PHASE3","title":"Intravesical BCG vs GEMDOCE in NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-02-07","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":870},{"nctId":"NCT05644041","phase":"PHASE2","title":"Intravesical Gem/Doce in Patients With NMIBC","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-03-01","conditions":"Urinary Bladder Cancer","enrollment":25},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":"Urinary Bladder Neoplasms","enrollment":107},{"nctId":"NCT07426705","phase":"PHASE4","title":"Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","startDate":"2026-02-15","conditions":"Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS","enrollment":100},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT07418489","phase":"NA","title":"Biotics Intervention Oriented to Rescue From Environmental Pollution Inflammatory Responses","status":"ENROLLING_BY_INVITATION","sponsor":"University of Turin, Italy","startDate":"2026-01-24","conditions":"Healthy 70 Street Market Vendors Working in Highly-polluted Areas of Turin","enrollment":70},{"nctId":"NCT06972615","phase":"PHASE2","title":"Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy","status":"NOT_YET_RECRUITING","sponsor":"BLATAM","startDate":"2026-04-01","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":37},{"nctId":"NCT04985877","phase":"NA","title":"Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota in Sarcopenia Elderly","status":"COMPLETED","sponsor":"Taipei Medical University","startDate":"2021-03-23","conditions":"Sarcopenia, Inflammation, Aging","enrollment":132},{"nctId":"NCT07219498","phase":"NA","title":"Effects of a 5-Week Probiotic Supplementation Intervention on Markers of Delayed Onset Muscle Soreness","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2026-02-05","conditions":"Exercise Induced Muscle Damage, Delayed Onset Muscle Soreness (DOMS)","enrollment":24},{"nctId":"NCT07341087","phase":"NA","title":"Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial","status":"NOT_YET_RECRUITING","sponsor":"King's College London","startDate":"2026-03-09","conditions":"Acne Vulgaris, Perimenopause, Skin Inflammation","enrollment":30},{"nctId":"NCT07399717","phase":"NA","title":"Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Anabio R&D","startDate":"2026-01-26","conditions":"Pneumonia, Pneumonia in Children","enrollment":330},{"nctId":"NCT03569553","phase":"","title":"A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2027-05-30","conditions":"Inhalational Anthrax","enrollment":100},{"nctId":"NCT03569514","phase":"","title":"Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2026-11-30","conditions":"Anthrax","enrollment":10},{"nctId":"NCT07388264","phase":"NA","title":"Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","status":"RECRUITING","sponsor":"Lindenwood University","startDate":"2025-06-15","conditions":"Gastrointestinal Symptoms, Constipation, Gut Health","enrollment":30},{"nctId":"NCT07377942","phase":"NA","title":"To Evaluate the Effect of Bacillus Subtilis Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults.","status":"ENROLLING_BY_INVITATION","sponsor":"Bioagile Therapeutics Pvt. Ltd.","startDate":"2025-09-16","conditions":"Healthy Participants Study","enrollment":46},{"nctId":"NCT07377994","phase":"NA","title":"To Evaluate the Effect of Bacillus Coagulans Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Bioagile Therapeutics Pvt. Ltd.","startDate":"2025-09-10","conditions":"Healthy Subjects (HS)","enrollment":46},{"nctId":"NCT06973174","phase":"","title":"Bacillus Cereus Invasive Infections in Preterm Neonates Hospitalized in French Hospitals","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2010-01-01","conditions":"Sepsis, Infections","enrollment":40},{"nctId":"NCT04752722","phase":"PHASE1, PHASE2","title":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","status":"RECRUITING","sponsor":"enGene, Inc.","startDate":"2021-04-22","conditions":"Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":350},{"nctId":"NCT04453293","phase":"PHASE3","title":"Immunization With BCG Vaccine to Prevent Tuberculosis Infection","status":"TERMINATED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2021-12-01","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT04165317","phase":"PHASE3","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":1068},{"nctId":"NCT07258303","phase":"NA","title":"Oral-Spray Bacillus Spore Probiotics for Periodontal Disease Prevention and Supprotive Treatment in the Elderly","status":"RECRUITING","sponsor":"Anabio R&D","startDate":"2025-12-20","conditions":"Periodontal Disease, Oral Deseases","enrollment":90},{"nctId":"NCT07283835","phase":"PHASE2","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","status":"RECRUITING","sponsor":"Lepu Biopharma Co., Ltd.","startDate":"2025-12-04","conditions":"Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer","enrollment":16},{"nctId":"NCT04630730","phase":"PHASE2","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2022-06-24","conditions":"Bladder Cancer","enrollment":46},{"nctId":"NCT06970964","phase":"NA","title":"Fermented Milk Drink With Lacticaseibacillus Paracasei Strain Shirota Helps Triathletes With Cold-Like Symptoms Before and After a Race","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2025-08-13","conditions":"Respiratory Tract Infections (RTI), Mucosal Immunity, Systemic Inflammation","enrollment":80},{"nctId":"NCT07341750","phase":"NA","title":"Effects of Bacillus Coagulans SNZ 1969 on Immune Health in Healthy School-aged Children","status":"RECRUITING","sponsor":"Sanzyme Biologics Private Limited","startDate":"2025-11-05","conditions":"Immunity","enrollment":100},{"nctId":"NCT06448767","phase":"NA","title":"The Effect of a Multispecies Probiotics on Autism Symptoms in Children","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2024-08-07","conditions":"Autism Spectrum Disorder","enrollment":110},{"nctId":"NCT07276009","phase":"NA","title":"Probiotics in Functional Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"Nordic Biotic Sp. z o.o.","startDate":"2026-01-05","conditions":"Functional Dyspepsia","enrollment":60},{"nctId":"NCT07320287","phase":"NA","title":"Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates","status":"NOT_YET_RECRUITING","sponsor":"Anabio R&D","startDate":"2026-01-07","conditions":"Functional Gastrointestinal Disorders (FGIDs), Weight Loss","enrollment":180},{"nctId":"NCT07212907","phase":"NA","title":"Probiotic and Ginger Supplement for Symptoms and Quality of Life in Functional Dyspepsia (SUBTILE)","status":"RECRUITING","sponsor":"Biocodex","startDate":"2025-12-22","conditions":"Functional Dyspepsia","enrollment":198},{"nctId":"NCT04997187","phase":"NA","title":"Effect of Bacillus Coagulans in Adults With With Functional Constipation","status":"COMPLETED","sponsor":"Pusan National University Yangsan Hospital","startDate":"2021-07-20","conditions":"Constipation - Functional","enrollment":80},{"nctId":"NCT07187492","phase":"PHASE4","title":"Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2025-09-20","conditions":"Functional Dyspepsia, Probiotics, Depression","enrollment":180},{"nctId":"NCT06747455","phase":"PHASE3","title":"BCG for Therapeutic Use Phase Ⅲ Clinical Trial","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-04-08","conditions":"BCG","enrollment":438},{"nctId":"NCT03711032","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-24","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":1397},{"nctId":"NCT07235228","phase":"NA","title":"Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients","status":"RECRUITING","sponsor":"The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz","startDate":"2025-11-21","conditions":"Irritable Bowel Syndrome","enrollment":20},{"nctId":"NCT07235215","phase":"NA","title":"Vivatlac in Irritable Bowel Syndrome II (ViIBS2)","status":"RECRUITING","sponsor":"The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz","startDate":"2025-11-21","conditions":"Irritable Bowel Syndrome","enrollment":200},{"nctId":"NCT04507126","phase":"PHASE2","title":"A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-03-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT02081326","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2015-06","conditions":"Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05180591","phase":"PHASE2","title":"Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05866536","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-05-04","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes type1","enrollment":100},{"nctId":"NCT07268612","phase":"","title":"Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2035-11","conditions":"Anthrax","enrollment":250},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT05768347","phase":"PHASE1","title":"Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-10","conditions":"Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT06223685","phase":"NA","title":"The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin","status":"COMPLETED","sponsor":"Pomeranian Medical University Szczecin","startDate":"2023-04-01","conditions":"Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth, SIBO","enrollment":129},{"nctId":"NCT07252778","phase":"PHASE2, PHASE3","title":"Effect of a Short-term Multi-strain Probiotic Supplementation in Endurance Athletes","status":"RECRUITING","sponsor":"Krzysztof Durkalec-Michalski","startDate":"2025-11-20","conditions":"Sports Nutrition, Biochemical Markers, Exercise Performance","enrollment":30},{"nctId":"NCT07200518","phase":"NA","title":"Effect of Probiotics After Neurosurgery","status":"RECRUITING","sponsor":"University Maribor","startDate":"2025-11-03","conditions":"Healing","enrollment":110},{"nctId":"NCT03528694","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-05-14","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":1018},{"nctId":"NCT02625961","phase":"PHASE2","title":"Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-10","conditions":"Bladder Cancer","enrollment":296},{"nctId":"NCT07241052","phase":"NA","title":"Oral-Spray Bacillus Spore Probiotic in Preventing and Supporting Treatment of Dental Caries in Children","status":"NOT_YET_RECRUITING","sponsor":"Anabio R&D","startDate":"2025-12-01","conditions":"Dental Caries","enrollment":130},{"nctId":"NCT04760353","phase":"NA","title":"The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"University Hospital Rijeka","startDate":"2021-11-10","conditions":"IBS - Irritable Bowel Syndrome, Obesity","enrollment":80},{"nctId":"NCT05672615","phase":"","title":"Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-21","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":42},{"nctId":"NCT03504163","phase":"PHASE2","title":"Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-27","conditions":"Bladder Cancer","enrollment":45},{"nctId":"NCT03933826","phase":"","title":"CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2019-07-09","conditions":"Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer","enrollment":570},{"nctId":"NCT06829823","phase":"PHASE2","title":"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":20},{"nctId":"NCT03022825","phase":"PHASE2, PHASE3","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2017-06-02","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT07207824","phase":"PHASE3","title":"DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, NMIBC","enrollment":182},{"nctId":"NCT07207941","phase":"NA","title":"Effect of Probiotics on Quality of Life, Activities of Daily Living and Anxiety in Post Stroke Patients","status":"NOT_YET_RECRUITING","sponsor":"National University of Malaysia","startDate":"2025-09-30","conditions":"Stroke","enrollment":110},{"nctId":"NCT06704191","phase":"PHASE1, PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":"Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":40},{"nctId":"NCT06765057","phase":"PHASE2, PHASE3","title":"Effect of Probiotics \"Psychobiotics\" on Depression and Metabolic Syndrome in Saudi Arabia","status":"RECRUITING","sponsor":"Roaa Ahmed Alkreadees","startDate":"2025-03-02","conditions":"Depression Anxiety Disorder","enrollment":60},{"nctId":"NCT07180186","phase":"","title":"Microbiota and Probiotic Therapy in Ulcerative Colitis Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-01-01","conditions":"Microbiota, Probiotic Therapy, Ulcerative Colitis","enrollment":70},{"nctId":"NCT04149574","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-15","conditions":"Urinary Bladder Neoplasms","enrollment":13},{"nctId":"NCT06351904","phase":"PHASE1","title":"A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy","status":"RECRUITING","sponsor":"Ractigen Therapeutics.","startDate":"2024-04-03","conditions":"Non-Muscle-Invasive Bladder Cancer (NMIBC)","enrollment":72},{"nctId":"NCT07164781","phase":"NA","title":"Effect of Use of Probiotics on Systemic Infection in Critically Ill Patients: a Double Blind, Randomized, Placebo-controlled Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Benha University","startDate":"2025-04-01","conditions":"Ventilator Acquired Pneumonia, Catheter Related Bloodstream Infection, Urinary Tract Infection","enrollment":100},{"nctId":"NCT04067011","phase":"PHASE2","title":"Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2019-08-12","conditions":"Anthrax","enrollment":210},{"nctId":"NCT07144475","phase":"PHASE4","title":"Comparison of Probiotic Effects on the Outcomes of Patients After Colorectal Cancer Surgery","status":"COMPLETED","sponsor":"Dharmais National Cancer Center Hospital","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":90},{"nctId":"NCT07123207","phase":"NA","title":"Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-08-04","conditions":"Mild to Severe Crohns Disease","enrollment":24},{"nctId":"NCT07114133","phase":"NA","title":"A Study on the Efficacy of Environmental Probiotics in Patients With Cat Hair Allergies","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-06-30","conditions":"Cat Allergy (Disorder), Allergic Rhinitis, Allergic Asthma","enrollment":100},{"nctId":"NCT05507671","phase":"PHASE3","title":"The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2021-05-27","conditions":"COVID-19","enrollment":556},{"nctId":"NCT06870344","phase":"NA","title":"IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-03-12","conditions":"Malaria Infection, Malaria Falciparum","enrollment":36000},{"nctId":"NCT07094711","phase":"PHASE2","title":"Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2025-09-30","conditions":"Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous","enrollment":48},{"nctId":"NCT06901739","phase":"NA","title":"Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity.","status":"RECRUITING","sponsor":"Celia Bañuls","startDate":"2025-04-15","conditions":"Obese Patients (BMI ≥ 30 kg/m²), Anxiety, Depressive Disorder","enrollment":120},{"nctId":"NCT07100743","phase":"NA","title":"Trial of Multi-Strain Probiotic Supplementation (Hexbio®) in Malaysian Patients With Drug-Resistant Epilepsy (ProbE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University of Malaysia","startDate":"2023-04-03","conditions":"Epilepsies Refractory","enrollment":78},{"nctId":"NCT06487975","phase":"NA","title":"Bacillus Subtilis in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Edinburgh","startDate":"2023-05-02","conditions":"Parkinson Disease","enrollment":48},{"nctId":"NCT06165354","phase":"NA","title":"Effects of LiveSpo X-SECRET in SupportiveTreatment of Vaginitis","status":"COMPLETED","sponsor":"Anabio R&D","startDate":"2023-12-01","conditions":"Vaginitis","enrollment":120},{"nctId":"NCT07064863","phase":"PHASE1, PHASE2","title":"A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2025-08-01","conditions":"NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer","enrollment":31},{"nctId":"NCT05922683","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2023-08-09","conditions":"Environmental Enteric Dysfunction, Stunting","enrollment":76},{"nctId":"NCT07046897","phase":"NA","title":"Analysis of the Gut Microbiota Composition After Consumption of Probiotic Bacteria","status":"RECRUITING","sponsor":"Lund University","startDate":"2024-11-12","conditions":"Microbiota Analysis in Healthy Subjects","enrollment":60},{"nctId":"NCT02015104","phase":"PHASE2","title":"Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-12-18","conditions":"Bladder Cancer","enrollment":32},{"nctId":"NCT06816017","phase":"PHASE1","title":"A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2025-06-15","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4554,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lactobacillus casei","genericName":"Lactobacillus casei","companyName":"Hospital Cristo Re","companyId":"hospital-cristo-re","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lactobacillus casei is a probiotic bacterium that colonizes the gut and modulates the intestinal microbiota and immune system to promote gastrointestinal and systemic health. Used for Gastrointestinal health maintenance, Antibiotic-associated diarrhea prevention, Immune system support.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}